[Antiviral action of combined use of rhizoma Polygoni cuspidati and radix Astragali on HSV-1 strain].
OBJECTIVE
The clinical action of combined use of Rhizoma Polygoni Cuspidati and Radix Astragali on HSV-1 was investigated with a view to developing a new antiviral drug.


METHODS
The action was analyzed by way of plaque reduction assay and median-effect principle.


RESULTS
In the HEp-2 cell system, if the combination ratio of Rhizoma Polygoni Cuspidati and Radix Astragali was 1(ED50):1(ED50) then, (1) In directly annihilating HSV-1 F strain, when the plaque reduction rate was 20%-80%, and the combination index was < 1.0, there was synergism. (2) In inhibiting the multiplication of HSV-1 F strain, when the plaque reduction rate was 20%-60%, and the combination index was < 1.0, there was also synergism. (3) In blockading HSV-1 F strain infection, when the plaque reduction rate was 20%-90% and the combination index was < 1.0, there was synergism. So this ratio of 1(ED50):1(ED50) should be the first choice for combination.


CONCLUSIONS
The treatment index of the above two Chinese medicinal herbs equals 10(3), and the cytotoxicity is not potentiated, indicating that the combination is helpful as a virucide for HSV-1 F strain.
Wang
Z
Z
Department of Oncogenic Virus, Virus Research Institute, Hubei Medical University, Wuhan 430071.
Cheng
Z
Z
Fang
X
X
D000998:Antiviral Agents / Q000494:pharmacology*; D027885:Astragalus propinquus; D004338:Drug Combinations; D004357:Drug Synergism; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology; D010946:Plants, Medicinal; D028502:Polygonum; D014407:Tumor Cells, Cultured / Q000821:virology
D000998:Antiviral Agents; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal